Yahoo Web Search

Search results

1. • 

     Earnings call: Kamada Limited reports robust Q1 2024 growth By Investing.com

     Investing.com· 1 day ago

     (NASDAQ:KMDA), a specialty biopharmaceutical company, has reported a strong start to the year with...

2. • Small Business - The Brewton Standard | The Brewton Standard

     The Brewton Standard· 2 days ago

     ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of & ...

3. • Study: For treating retinopathy of prematurity, UB-led research proves that ranibizumab is safe

     UB Reporter· 9 hours ago

     A University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP occurs in low ...

4. • 

     Agenus (AGEN) Q1 2024 Earnings Call Transcript

     Motley Fool via Yahoo Finance· 3 days ago

     Malon Fakim at City of Hope. He is investigating BOT and BAL, combined with standard-of-care FOLFOX, plus bevacizumab, in first-line metastatic or...

5. • Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...

     Nature· 7 days ago

     Tregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC patients ...

6. • 

     What to know about cervical cancer

     Medical Xpress· 5 days ago

     Part of the reproductive system, the cervix connects the vagina to the uterus, also known as the womb. By collecting cervical cells (called the Pap smear...

7. • Q1 2024 Agenus Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 3 days ago

     I want to highlight is the full Fox three b. regimen with Dr. Marwan for team at City of Hope he is investigating bar and bound combined with standard of care, full Fox plus bevacizumab ...

8. • 

     Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as...

     FOX 23 News Albany· 4 days ago

     Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...

9. • 

     SHP report claims hospitals overcharging for oncology drugs

     Winston-Salem Journal· 2 days ago

     The latest commissioned report by state Treasurer Dale Folwell — released Wednesday — determined...

10. • Trehalose is enabling life-changing protein therapeutics and exosomes

      Nature· 3 days ago

      Trehalose is vital to the biopharma industry. Manufacturers of monoclonal antibodies and other protein therapeutics use this saccharide to stabilize molecules that would otherwise be degraded ...